SAM
UTHR icon

Senzar Asset Management’s United Therapeutics UTHR Stock Holding History

Senzar Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,625
Closed -$297K – 16
2018
Q2 		$297K Sell
2,625
-44,375
-94% -$4.88M 0.86% 23
2018
Q1 		$5.28M Buy
+47,000
New +$5.97M 1.67% 21

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Senzar Asset Management's UTHR Position: Q3 2018 in Review

Senzar Asset Management sold out of United Therapeutics (UTHR) in Q3 2018, closing a stake of 2,625 shares — an estimated $297K sold.

Senzar Asset Management first reported a position in UTHR in Q1 2018 and held it in 2 quarters. The position peaked at $5.28M in Q1 2018. 367 funds tracked by Wall St. Rank hold UTHR as of Q3 2018.

  • Senzar Asset Management reported no remaining United Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Senzar Asset Management sold 2,625 United Therapeutics shares in Q3 2018, an estimated $297K.
  • Senzar Asset Management first reported a position in United Therapeutics in Q1 2018 and held it in 2 quarters.
  • Senzar Asset Management's United Therapeutics position peaked at $5.28M in Q1 2018.
  • 367 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2018.

Based on Senzar Asset Management's 13F filing for Q3 2018.